Navigation Links
Zydus Pharmaceuticals USA Inc. Issues Voluntary Nationwide Recall of Warfarin 2 mg Tablets, Lot MM5767, Expiration Date June 2014, Due to Oversized Tablets

PENNINGTON, New Jersey, June 12, 2013 /PRNewswire/ --

Zydus Pharmaceuticals USA Inc. is voluntarily recalling one lot of Warfarin 2 mg Tablets, Lot # MM5767, expiration date June 2014 to the retail level. Four tablets of Warfarin 2 mg Tablets, Lot MM5767, have been found to be oversized in one product complaint.

Ingestion of a greater than intended dose of Warfarin, could lead to an increased pharmacological effect of warfarin. As a result, patients would be more likely to develop bleeding as an adverse reaction and in some patients that bleeding into a critical organ (mostly the central nervous system) could be fatal. The risk of bleeding is increased if overdosing is repeated continuously on a daily basis.

Zydus has not received any reports of adverse events or any additional product complaint related to this lot to date, but as a precautionary measure, Zydus is recalling lot MM5767 from the distribution.

The product is used as prophylaxis and treatment of venous thrombosis and its extension, pulmonary embolism (PE), prophylaxis and treatment of thromboembolic complications associated with atrial fibrillation (AF) and/or cardiac valve replacement and reduction in the risk of death, recurrent myocardial infarction (MI), and thromboembolic events such as stroke or systemic embolization after myocardial infarction. Product is packaged in HDPE Bottle of 1000's count, which may have been dispensed to patients in smaller bottles. The only lot affected of Warfarin 2 mg Tablets being recalled is Lot MM5767.

The product can be identified by its NDC # 6838205310.  The product was distributed nationwide in the United States to wholesalers/distributors, retailers and mail order providers, from November 2012 to December 2012.

Zydus has notified its direct account customers by sending the recall notification letter by FedEx next day air service and is working with customers to arrange for product return.

Anyone with an existing inventory of this particular Lot MM5767 of Warfarin 2 mg Tablets should stop use and distribution, quarantine the recalled lots immediately and call INMAR at 1-800-967-5952 between the hours of 7 a.m. to 4 p.m. CST, Monday through Friday, to arrange for their return. In case patients have tablets of this lot of product, make sure all the tablets are of the same size and if unsure, patients should consult their dispensing pharmacy.

If you have any question about product safety issue, then please call Zydus Pharmaceuticals Drug Safety/ Medical Affairs at 1-877-993-8779, Option# 2. Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this particular lot of Warfarin 2 mg Tablets.

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.

SOURCE Zydus Pharmaceuticals USA Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Zydus fait une percée avec LIPAGLYN, première NEC indienne mise sur le marché
2. Zydus Pioneers a Breakthrough With LIPAGLYN, Indias First NCE to Reach the Market
3. Zydus Demonstra Pioneirismo com o Inovador LIPAGLYN, Primeiro NCE da Índia a Entrar no Mercado
4. Adamas Pharmaceuticals To Report Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia In Parkinsons Disease
5. Access Pharmaceuticals Signs US License Agreement With AMAG Pharmaceuticals For MuGard
6. HemaQuest Pharmaceuticals Completes Patient Enrollment in Phase 2b Clinical Study of HQK-1001 in Patients with Sickle Cell Disease
7. Oramed Pharmaceuticals to Present at IATI-BioMed Conference in Israel
8. DelMar Pharmaceuticals, Inc. Investor Presentation Now Available for On-demand Viewing at
9. Valeant Pharmaceuticals Announces Filing Of Preliminary Base Shelf Prospectus
10. Ampio Pharmaceuticals Issues Statement Regarding Misleading Blog
11. Actinium Pharmaceuticals, Inc. Receives $3.5m from Exercise of Warrants
Post Your Comments:
(Date:10/12/2015)... October 12, 2015 ... to grow at 7.2% CAGR, microscopy market ... rising focus on nanotechnology, technological advancements, and ... report available with ... . --> Complete report on ...
(Date:10/12/2015)...   Royal Philips (NYSE: PHG, AEX: PHIA), ... a collaboration with Genomic Health , Inc. (NASDAQ: ... diagnostic tests, to leverage Philips digital pathology tools in ... testing processes.    --> ... samples and plays a crucial role in the diagnosis ...
(Date:10/12/2015)... , Oct. 12, 2015 Indivior PLC (LON: ... District of Delaware granted the Company,s ... Pharmaceuticals, Abbreviated New Drug Application (ANDA) No. 205299 to market ... (buprenorphine and naloxone) Sublingual Film (CIII) in the ... --> Since August 2013, Indivior has received Paragraph IV ...
Breaking Medicine Technology:
(Date:10/12/2015)... ... 2015 , ... The American Society of Clinical Hypnosis (ASCH) ... and clinical training in a health care discipline. , Many practitioners claim ... losing weight, managing pain, or stopping smoking, etc. Frequently, extravagant statements and guarantees ...
(Date:10/12/2015)... ... October 12, 2015 , ... AcousticSheep LLC, creators of ... in honor of Breast Cancer Awareness Month. During the month of October, ... a SleepPhones® Classic product to a breast cancer patient at the Cleveland Clinic. ...
(Date:10/12/2015)... ... October 12, 2015 , ... To help ... its charitable donation to the National Breast Cancer Foundation. The National Breast Cancer ... breast cancer through early detection, education, and support services. , The annual campaign ...
(Date:10/12/2015)... ... October 12, 2015 , ... NFL football fans who are interested in having an opportunity to ... CLICK HERE to donate to Smile for a Lifetime (S4L) Foundation and gift ... all-inclusive trip to the 2016 NFL Super Bowl! , Donors contributing $20.00 or more between ...
(Date:10/12/2015)... , ... October 12, 2015 , ... The translation for ... seamless migration of complete ARIS installations into the Microsoft world. The ARIS models ... As Microsoft Visio® is very familiar for both IT and Office users it is ...
Breaking Medicine News(10 mins):